Fasting glucose increased in the tesamorelin group at @ weeks ( mean change , @ mg/dL -LSB- @ % CI , @-@ mg/dL -RSB- vs @ mg/dL -LSB- @ % CI , -@ to @ mg/dL -RSB- in the placebo group ; treatment effect , @ mg/dL -LSB- @ % CI , @-@ mg/dL -RSB- ; P = @ ) , but changes at @ months in fasting glucose ( mean change , @ mg/dL -LSB- @ % CI , -@ to @ mg/dL -RSB- with tesamorelin vs @ mg/dL -LSB- @ % CI , -@ to @ mg/dL -RSB- with placebo ; treatment effect , @ mg/dL -LSB- @ % CI , -@ to @ mg/dL -RSB- ; P = @ overall across time points ) and @-hour glucose ( mean change , -@ mg/dL -LSB- @ % CI , -@ to @ mg/dL -RSB- vs -@ mg/dL -LSB- @ % CI , -@ to @ mg/dL -RSB- , respectively ; treatment effect , @ mg/dL -LSB- @ % CI , -@ to @ mg/dL -RSB- ; P = @ overall across time points ) were not significant .